GREY:ATBPF - Post by User
Comment by
MrMugsyon Oct 27, 2021 9:32am
167 Views
Post# 34053828
RE:RE:RE:RE:RE:Dan and next week
RE:RE:RE:RE:RE:Dan and next weekRight - I think the release says it as "dosing regimen for OA indication requires additional investigation." Finding the right amount of painkiller while keeping liver enzymes at bay over the longrun is the challenge. Something that doesn't confuse the liver with external H2S while it's also trying to produce its own.
Let's say they come so close but just can't find the right combo. Worst case - I would like to see an attempt to supplement other pain regimens with OTENA. Not saying we need to go that far ... but ... there seems to be a worst-case chronic scenario (at least in my head).
While we wait for chronic tweaking - we attack on the acute front. In my opinion.
Inthepez wrote: Failure is a strong word. GI safety: excellent. Analgesia: excellent.
This liver enzyme elevation is a dosing issue.
MasterAlgae wrote: Nor is the fault of the CEO that the lead drug failed.
The CEO got a boat-load of after-tax money from the retail investor - that is a success, job done.
Most of us are not happy with the failure but that's the risk.
Forestview wrote: You should email him and vent your frustrations directly to him. Doing it here is pointless.
dan@antibethera.com
Layth1990 wrote: He still can save the company if he resigns